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II. ABSTRACT 
 
 
Research indicates that nucleus accumbens dopamine (DA) is an important 
component of the neural circuitry regulating behavioral activation and effort-related 
processes.  In humans, psychiatric symptoms such as anergia and psychomotor 
retardation reflect pathologies in behavioral activation.  These motivational symptoms are 
fundamental aspects of depression and other disorders.  Drugs such as reserpine and 
tetrabenazine deplete monoamines, including dopamine, and induce depressive like 
behaviors in humans.  Tetrabenazine inhibits vesicular monoamine transporter-2 
(VMAT2), and has been shown to induce depressive symptoms, including psychomotor 
retardation, lethargy, fatigue and anergia, in some human patients.  In rodents, disruptions 
in activational or effort-related aspects of motivation are sometimes studied using tasks 
that assess effort-based choice behavior.  Organisms are capable of making effort-related 
decisions based upon assessments of motivational value and response costs.  Research 
involving choice tasks has shown that rats with impaired DA transmission reallocate their 
instrumental behavior away from food-reinforced tasks with high response costs, and 
instead select less effortful food-seeking behaviors.  The current study investigated the 
effects of tetrabenazine on effort-related choice behavior.  Administration of 
tetrabebazine at doses that reduce accumbens DA levels (0.5-1.0 mg/kg) alters effort-
related choice behavior in rats responding on a concurrent FR5/chow feeding choice task, 
a concurrent progressive ratio choice task, and T-maze barrier choice procedure.  Initial 
evidence indicates that these effects of tetrabenazine on effort-related choice behavior 
can be reversed by co-administration of the adenosine A2A antagonist MSX-3.  Taken 
together, these results indicate that administration of low doses of tetrabenazine can alter 
effort-related choice behavior, biasing animals towards low effort alternatives.  These 
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findings may be related to the ability of monoamine depleting agents such as 
tetrabenazine to blunt behavioral activation and induce psychomotor retardation, anergia 
and fatigue in humans, and this research could be useful for the development of drug 
treatments for effort-related motivational symptoms in humans.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
III. BACKGROUND AND SIGNIFICANCE 
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According to The National Institute of Mental Health, depression is currently the 
leading cause of disability in the United States (WHO 2004).  Major depression is a 
heterogeneous disease, with symptoms that include, but are not limited to: psychomotor 
slowing and deficits in emotional processing and cognitive function (APA 2000).  The 
absence of energy (i.e., anergia) is a depressive symptom that is reported more often by 
depressed patients compared to anxiety-related symptoms (Salamone et al. 2006).   
Anergia is the single symptom of depression most strongly correlated with a lack of 
social functioning and thus decreased work productivity due to days in bed and days of 
lost work (Swindle 2001).  As is a particularly difficult symptom to treat, accruing 
evidence suggests that current first-line pharmacotherapies (e.g., SSRIs) do not 
adequately address motivational and reward-processing deficits in depression (Dunlop 
and Nemeroff, 2007; McCabe et al., 2009; Price et al., 2009), and the presence of angeric 
symptoms is a predictor of poor response to treatment (Spijker et al., 2001). 
The specific neural pathology underlying depression is largely unknown, 
however, depression seems related to decreased transmission of monoamines.  Chemical 
analyses of cerebrospinal fluid in patients suffering from untreated depression, reveals 
decreases in 5-HIAA (a serotonin metabolite) decreases in total norepinephrine 
metabolism, and decreases in HVA (a DA metabolite).  Additionally, decreasing 
monoamine synthesis acts to increase depressive symptoms (Meyer et al. 2006).  This 
line of research aided the development of the monoamine theory of depression.  This 
theory postulates that depression is associated with low levels of monoamines, 
particularly serotonin (5-HT) and norepinephrine (NE) (Maletic, 2007).  Imaging studies 
of patients with untreated depression revealed a high receptor density for monoamine 
oxidase A (MAO-A), which metabolizes these neurotransmitters (Maletic 2007).  A loss 
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of MAO-A interacts with specific transporter densities (i.e., 5-HT and NE) resulting in 
depressive illness (Maletic 2007; Meyer et al. 2006).  Therefore, the most common 
prevailing pharmacological treatment for depression is selective serotonin reuptake 
inhibitors (SSRIs).   SSRIs work by increasing the extracellular level of the monoamine 
5-HT by inhibiting its reuptake into the presynaptic cell.  This effectively increases the 
level of 5-HT available in the synaptic space to bind with the postsynaptic receptor.  
However, a major problem with this treatment of depression is the large time gap 
between starting the medication and the observed therapeutic effect.  Working within 
minutes in vivo, SSRIs potently block 5-HT transporters, increasing extracellular levels 
of 5-HT.  Yet, despite these immediate extracellular increases, the therapeutic effects 
(i.e., mood elevation) are not seen until weeks later.  Furthermore, even with remission of 
some emotional symptoms, patients often report fatigue and psychomotor slowing 
(Cousins and Salamone 1994; Treadway and Zald 2010).   
The lack of effective patient response to the current reigning pharmacological 
treatment demands further research.  It is particularly necessary to elucidate the neuronal 
mechanisms underlying the pervasive behavioral symptoms: psychomotor slowing and 
behavior directed motivational tasks.  Motivation has been defined as the set of processes 
that organisms use to regulate the probability, proximity and availability of significant 
stimuli (Salamone 1992; Salamone and Correa 2002).  Motivated behaviors are further 
broken down to include both directional and activational components (Salamone 1988).  
Directional aspects refer to motivated behavior as either directed toward or away from a 
stimulus (Salamone and Correa 2002).  Alternatively, the activational aspects refer to the 
instrumental behaviors often characterized by a high degree of vigor, persistence, and 
work output (Salamone 1988, 1992; Salamone and Correa 2002; Salamone et al. 2007).  
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The concept that motivated behaviors have this activational component is not new to the 
fields of psychology, neurology, or psychiatry.  Pathologies that involve effort-related 
aspect of motivation are seen as an important defining feature of many psychiatric 
syndromes.  In fact, clinical literature emphasizes the importance of motivational 
symptoms as related to energy and effort-related expenditure (Tylee et al. 1999; Stahl 
2002; Salamone et al. 2006; Treadway and Zald 2010).  This includes, but is not limited 
to, the psychomotor slowing, apathy, anergia, and fatigue that typifies major depression, 
parkinsonism and other disorders.  Again, the severity of these symptoms in depressed 
patients is directly related to difficulties with social functioning, employments and 
treatment outcomes (Treadway and Zald 2011; Tylee et al. 1999; Stahl, 2002). 
The neuronal basis of energy-related impairments in the functioning of depressive 
patients is still being characterized; however, there is considerable evidence that 
implicates central dopamine (DA), especially in the nucleus accumbens, as well as the 
neocortex and limbic system.  Research suggests that the compromised DA transmission 
in the basal ganglia, particularly in nucleus accumbens, is associated with depression and 
may underlie fatigue, anergia, and problems with behavioral activation.  In fact, depleting 
or blocking DA in these striatal regions can induce psychomotor slowing and 
parkinsonian motor symptoms (i.e. tremor).  Therefore, blocking of depleting DA 
expression in nucleus accumbens can induce both behavioral inactivation and tremulous 
movements.  Within the striatal regions, DA and adenosine receptors are highly 
expressed, and have antagonistic interactions.  Due to this antagonistic relationship, 
adenosine A2A antagonists are currently in clinical trials to treat parkinsonian tremors.  
However, these drugs have yet been evaluated for their potential to reverse the 
psychomotor symptoms of depression.  The literature on Parkinson’s disease makes a 
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strong case for alleviating symptoms clustered around atypical movement and activation. 
Given the similarities in expression of anergic symptoms between Parkinson’s disease 
and depression, further work is needed to determine how the pathways implicated in 
Parkinson’s disease correlate to those underlying depression.  Depression as a common 
“non-motor” symptom of Parkinson’s disease suggests the both disorder share a common 
neurological substrate, with alterations in the interaction of DA-adenosine 
neurotransmission as the biological basis of depression.  
It was hypothesized that pharmacological manipulations that serve to produce 
depressive-like motor and behavioral symptoms in humans will also produce effort-
related choice impairments in rodents.  In fact, this combination of behavioral and 
pharmacological methods could be employed as an animal model of depression in which 
to test the efficacy of putative antidepressants, novel treatments, and change the 
relationship between our understanding of depression and psychomotor retardation.  The 
present study worked to expand upon what is known about nucleus accumbens DA in 
effort-related processes, by determining if pharmacological manipulations associated 
with depression-like symptoms can induce effort-based dysfunctions in rats.  It is 
suggested that highly active, instrumental behaviors prompted by conditioned stimuli are 
those most sensitive to interference with DA systems (Salamone 1991).  For instance, 
instrumental responding for food is affected by accumbens DA manipulations, such as 
DA antagonism or depletions; however these effects are schedule-dependent.  Further, 
DA antagonism or depletions in these areas have little to no effect on schedules that have 
low to moderate ratio requirements, such as a fixed ratio of one pellet per single lever 
press (FR1 schedule).  However, increasing the ratio requirement of the operant task from 
FR1 to an FR5 schedule increases the suppressant effects of an accumbens DA depletion 
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(Salamone et al. 1991, 2001; Ishiwari et al. 2004a).  This evidence suggests that an 
interference with accumbens DA selectively impairs activational aspects of motivation, 
while leaving directional aspects intact.  Thus, in addition to its role in the exertion of 
effort, accumbens DA is implicated in the mediation of effort-related choice tasks 
(Salamone et al. 2003; Ishiwari et al. 2004a; Mingote et al. 2005).   
With the body of evidence citing the clinical relevance of fatigue and other forms 
of energy or effort-related motivation dysfunctions in psychiatric disorders, it is critical to 
develop animal models of illness.  In particular, an animal model of depression would be 
necessary for evaluating current treatments, identifying therapeutic targets, and 
investigating the mechanisms involved.  Several behavioral tasks have been useful in 
assessing the effects of antidepressants medications in rodents, such as the forced swim 
test, tail suspension task, chronic mild stress, and the social defeat paradigm (Duman 
2010; Yan et al. 2010).  Using these behavioral task to model depression in rodents does 
not allow for an accurate or reliable approach to the multifaceted disorder.  Therefore, the 
concurrent choice procedure is favored with its focus on modeling specific behavioral 
depressive symptoms by targeting effort-related choice behavior. 
  This experiment focused on the behavioral and cellular effects of monoamine-
depleting agents that induce or exacerbate depressive symptoms in humans.  Monoamine-
depleting agents, such as reserpine and tetrabenazine act by blocking monoamine storage 
to induce behavioral impairments.  These pharmacological agents have been used for 
decades in efforts to create working models of depression in animal research.  The drug 
reserpine was first introduced as a tranquilizing agent to treat hypertension, before 
removed due to patient report of developing major depression.  Subsequent research has 
found reserpine to induce behavioral depression as a result of depleting all monoamines.  
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In fact, when administered in high doses, reserpine can induce catalepsy and tremulous 
movements characteristic of Parkinson’s disease.  These pharmacological effects could 
potentially create a rodent reserpine-model of depression to test the efficacy of punitive 
and novel antidepressant treatments.  The drug tetrabenazine was marketed for the 
treatment of hyperkinetic movement disorders, such as Huntington’s chorea, but has a 
high incidence of inducing depressive symptoms.  Similar to reserpine, tetrabenazine-
induced depressive symptoms may be due to the degradation of monoamines.  
However, preliminary data indicates that tetrabenazine is more consistently 
effective than reserpine at producing the desired alterations in effort-related choice 
behavior.  Therefore, the proposed experiment sought to characterize the effects of 
tetrabenazine on effort-related choice behavior.  For these reasons, this experiment was 
designed to study the ability of pharmacological conditions associated with the induction 
of depressive symptoms in humans to induce grossly similar effort-based dysfunctions in 
rats. 
 
IV. MATERIALS & METHODS 
 
Subjects: 
 In this study, adult male Sprague-Dawley rats (n=16; Harlan Sprague Dawley, 
Indianapolis, IN, USA) were used as subjects.  These animals, with no prior drug 
experience and minimum handling were paired-housed in a colony maintained at 23oC, 
with a 12 hour light/dark cycle (lights on at 0700).  Water was available ad lib in the 
home cages as all times.  However, the rats that were tested in operant boxes were food 
restricted to 85% of their free-feeding body weight for initial operant training and 
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allowed modest weight gain during the studies.  At the beginning of the experiment the 
rats weighed between 279-299 grams.  These animal protocols were approved by the 
University of Connecticut Institutional Animal Care and Use Committee, and the studies 
were conducted according to NIH guidelines for animal care and use. 
 
Pharmacological Agents: 
 This study used intraperitoneal (IP) injections of TBZ (R&D Systems) and 
reserpine (Tocris).   TBZ was dissolved in an acidified solution and reserpine in 0.3% 
tartaric acid, which were also used for the vehicle control condition.  For the three weeks 
of the TBZ experiment, the trained rats received the same treatment administered 90 
minutes prior to testing: vehicle IP, 0.5 mg/kg TBZ, or 1.0 mg/kg TBZ. 
 
 
 
Behavioral Procedure: 
To study the effects of a monoamine depleting agent tetrabenazine, subjects were 
tested on a task that assessed effort-related choice behavior (i.e., the concurrent lever 
pressing chow intake task, see Salamone et al. 1991).   Food restricted rats will be trained 
on this task in standard operant conditioning chambers (28 cm x 23 cm x 23 cm; Med PC, 
Inc.) during the light period. Animals were trained in 30 minute sessions, 5 days per 
week.  In the first week of training, all rats were trained to lever press on a fixed ratio 1 
schedule, where one lever press results in the animal receiving one 45 mg high 
carbohydrate food pellet (Research Diets Inc., New Brunswick, NJ).  In the second week, 
animals were shifted to a fixed ratio 5 schedule, where fiver lever presses results in one 
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pellet.  This schedule was maintained for 3-4 weeks until the rats achieved a stable 
baseline performance (i.e., >1000 lever presses per session).   After performance of the 
FR5 schedule was stable, weighed amounts of laboratory chow (ProLab, Lab Diet, 
Brentwood, MO; typically 15-25 g, three large pieces) were concurrently available on the 
floor of the chamber during the 30 minutes FR 5 sessions.  The rats continued to perform 
on this concurrent feeding procedure for several weeks prior to the introduction of TBZ.  
At the end of each session, rats will be immediately removed from the operant chambers. 
Food intake was determined by weighing the remaining food, including collected 
spillage, while a computer program recorded lever pressing.  This experiment used a 
between-groups design; with each rat receiving only one dose of tetrabenazine once a 
week carried out for three weeks.  
 
 
Research Overview: 
As previously noted, the behavioral effects of depression are those most often 
reported as the most debilitating, and consequently result in the most days of lost 
productivity.  Additionally, these motor-related symptoms are the most difficult to treat 
effectively with putative antidepressant medications. This evidence indicates that the 
basic animal studies described above are potentially relevant for understanding 
depression’s effort-related dysfunction in humans.  Such studies are possible through the 
strikingly similar brain circuitry involved in effort-related functions in rats and the 
systems thought to undermine the energy-related dysfunction caused by depression.  
Capitalizing on this similarity, the proposed animal studies can lead to the development 
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of animal models for these symptoms to test the efficacy of current pharmacological 
treatments, as well as novel treatments. 
 
Two pharmacological manipulations will be tested using the same behavioral choice  
procedure: 
 
Group 1:  The drug reserpine was first introduced as a tranquilizing agent to treat 
hypertension, before removed due to patient reports of developing major depression.  The 
side effect of the monoamine depleting agent reserpine is consistent with the body of 
literature documenting the effects of interference with nucleus accumbens DA on effort-
related choice.  This experimental group tested reserpine for its effects on effort-related 
choice behaviors.  Similar to the function of DA antagonists, reserpine also induces 
psychomotor slowing and parkinsonian motor symptoms by blocking of depleting DA 
expression.  Additionally, subsequent research has found reserpine to induce behavioral 
depression as a result of depleting all monoamines (Huang 2004).  Due to the 
pharmacological effects of reserpine, it was hypothesized that systemic injections of 
reserpine would produce a shift in the allocation of effort on the concurrent FR5/chow 
feeding procedure.  
 
Group 2: The second pharmacological agent tested for its effects on effort-related 
behaviors was tetrabenazine (TBZ), a VMAT2 inhibitor.  Evidence from related animal 
studies support the idea that pharmacological agents such as TBZ produce depression-
like behaviors, including psychomotoring slowing, fatigue, and anergia.  It was 
hypothesized that by inhibiting vesicular storage of monoamines, TBZ would decrease 
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extracellular DA levels, and dose dependently decrease lever pressing and increase the 
consumption of free feeding chow on the concurrent FR5/chow procedure. 
Experiment 1: Systemic administration of resperine on the concurrent FR5/chow  
feeding procedure: a dose response curve 
Rats were trained on the concurrent FR5/chow feeding procedure as described 
below.  The following treatments were used: 0.3% tartaric acid vehicle, 0.625mg/kg 
reserpine IP (90 min before testing), 0.75mg/kg reserpine (90 min before testing), and 
1.0mg/kg reserpine (90 min before testing).  Experiment 1 used a within-groups design; 
with all rats receiving all drug treatments in their particular experiment in a randomly 
varied order (one treatment per week). 
 
 
Experiment 2: Systemic administration of tetrabenazine on the concurrent  
FR5/chow feeding procedure: a dose response curve 
 Rats were trained on the concurrent FR5/chow feeding procedure as described 
below.  The following treatments were used: acidified vehicle, 0.5mg/kg TBZ IP (90 min 
before testing) and 1.0mg/kg TBZ (90 min before testing).  Experiment 1 used a within-
groups design; with all rats receiving all drug treatments in their particular experimental 
in a randomly varied order (one treatment per week). 
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V. RESULTS 
 
Tetrabenazine produced a consistent behavioral shift from lever pressing to free 
feeding chow consumption in the first week of testing (Fig. 1).  At week one, there was a 
significant effect of drug treatment on decreasing lever pressing at 0.5mg/kg [F(2, 26) = 
86.643; P<0.05] and 1.0mg/kg [F(2, 26) = 43.653; P<0.05] doses compared to the 
vehicle.  There was also a significant effect of the tetrabenazine treatment on chow intake 
at 1.0mg/kg dose [F(2,26) = 22.235; P<0.05].  
In week two, the administration of tetrabenazine maintained the significant shift 
in lever pressing to chow consumptions at the 1.0mg/kg dose (Fig. 2).  Week two, 
produced a significant effect of the drug treatment on decreasing lever pressing at 
1.0mg/kg [F(2,26) = 86.643; P<0.05].  There was also a significant effect of the 
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tetrabenazine treatment on chow intake at 1.0mg/kg [F(2,26) = 21.327; P<0.05]. The dose 
of 0.5mg/kg TBZ no longer produced significant results at week two. 
In week three, the administration of tetrabenazine maintained the significant shift 
in lever pressing to chow consumptions at the 1.0mg/kg dose (Fig. 3).  Week three, 
produced a significant effect of the drug treatment on decreasing lever pressing at 
1.0mg/kg [F(2,26) = 33.641; P<0.05].  There was also a significant effect of the 
tetrabenazine treatment on chow intake at 1.0mg/kg [F(2,26) = 13.911; P<0.05].  
The administration of 0.75mg/kg dose of reserpine suppressed lever pressing with 
repeated use as compared to week one, but had no significant effect of chow intake across 
the three week experiment (Fig. 4).  There was a significant decrease in lever pressing at 
week two and three (P<0.05) compared to week one. 
VI. DISCUSSION 
 
 Motivation is a complex process, and several behavioral approaches have been 
used to study the impact of drugs administration on performance in effort-related choice 
procedures. Under these conditions, animals were able to select between two reinforcers 
that could be obtained through distinct instrumental behaviors (Salamone 2010b; 
Salamone et al. 1994). In the present study, the rats responded on a concurrent FR5/chow 
choice task. The monoamine depletion as a result of TBZ administration produced a 
significant alteration in the relative allocation of behavior, quantified by a decrease in 
lever pressing, but increase in chow consumption (Fig. 1-3). The present results are 
consistent with previous studies that determined increased ratio requirements on operant 
tasks increases the suppressant effect of DA depletions (Salamone et al. 1991, 2001; 
Ishiwari et al. 2004a). Additionally, previous studies have also supported that modest 
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doses of DA antagonists, with varying degrees of selectivity, all decrease lever pressing 
and increase chow intake in rats responding to this same task (Salamone et al. 1991).  The 
findings from the present study are consistent with the hypothesis that pharmacological 
manipulations that disrupt monoamine storage (i.e. TBZ) can produce effort-related 
choice impairments, with these behavioral shifts directly related to the actions on nucleus 
accumbens DA (Salamone et al. 2006, 2007, 2010; Meyer et al. 2011). TBZ reversibly 
binds with a high affinity to the vesicular monoamine transporter-2 (VMAT-2) (Meyer et 
al. 2011; Guay 2010).  In so doing, TBZ effectively inhibits vehicular storage of cytosolic 
monoamines, including serotonin, norepinephrine, and dopamine.  Although reserpine 
and TBZ work through a similar mechanism to inhibit monoamine storage, they have 
different mechanisms of action.  Reserpine serves as an irreversible inhibitor of both 
VMAT-1 and VMAT-2 (Peter et al. 1996).  TBZ and reserpine produced effort-related 
impairments on the concurrent FR5 procedure whereby lever pressing was reduced and 
chow consumption increased.  However, the effect of reserpine sensitizes with repeated 
administration, and does not provide stable baseline for repeated measures studies.  
Further, the motor effects of reserpine become severe with repeated administration, as 
rats show akinesia, incoordination, catalepsy, and tremulous jaw movements (Huang 
2004).  
This may be related to the difference in the mechanism of action of reserpine as 
compared to TBZ.  It is evident then that TBZ is more consistently effective than 
reserpine at producing alterations in effort-related choice behavior.   
Is it indicated then that these basic animal studies are potentially relevant for 
understanding the effort-related dysfunctions in.  There also is a striking similarity 
between the brain circuitry involved in effort-related functions in rats, and the systems 
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thought to be involved in energy-related dysfunction in depression (Salamone et al. 2006, 
2007, 2010; Treadway and Zald 2010).  This line of evidence suggests there is a degree 
of efficacy with which TBZ can induce effort-based dysfunctions in rodent models that 
closely mirror the depression-like symptoms affecting energy acquisition in humans. 
Future studies will assess the ability of several other conditions that are related to 
depression, such as pro-inflammatory cytokines, to induce effort-related dysfunctions in 
rats. Preliminary research indicates that an increase in pro-inflammatory cytokines has 
been associated with decreases in insulin and glucocorticoid receptor sensitivity, which 
promotes metabolic and neuroendocrine disruption (Weisler-Frank et al. 2005; Maletic 
2007). Symptomatically, these disruptions may be experienced as the fatigue that is 
associated with decreased behavioral activation experienced with depression. (Tsigos and 
Chrousos 2002; Maletic 2007). In addition, a TBZ animal model of depression can 
determine if these dysfunctions are sensitive to experimental and putative 
pharmacological treatments, such as the adenosine A2A antagonist MSX-3 and bupropion 
respectively.  
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VIII. FIGURE CAPTIONS 
 
Figure 1. The effects of tetrabenazine to dose-dependently induce changes in behavioral 
performance on the concurrent lever pressing/chow feeding procedure in week one.  Rats 
received IP injections of an acidified vehicle (VEH), 0.5mg/kg tetrabenazine (0.5 TBZ), 
or 1.0mg/kg tetrabenazine (1.0 TBZ). (A) Mean (±SEM) number of lever presses (FR5 
schedule during the 30 minutes session. (B) Mean (±SEM) gram quantity of chow intake. 
TBZ significantly suppressed lever pressing activity as compared to vehicle at 0.5mg/kg 
(*p<0.05) and 1.0mg/kg (*p<0.05).  TBZ significantly increased chow consumption at a 
dose of 1.0mg/kg (*p<0.05). 
 
Figure 2. The effects of tetrabenazine to dose-dependently induce changes in behavioral 
performance on the concurrent lever pressing/chow feeding procedure in week two.  Rats 
received IP injections of an acidified vehicle (VEH), 0.5mg/kg tetrabenazine (0.5 TBZ), 
or 1.0mg/kg tetrabenazine (1.0 TBZ). (A) Mean (±SEM) number of lever presses (FR5 
schedule during the 30 minutes session. (B) Mean (±SEM) gram quantity of chow intake. 
TBZ significantly suppressed lever pressing activity as compared to vehicle at 1.0mg/kg 
(*p<0.05).  TBZ significantly increased chow consumption at a dose of 1.0mg/kg 
(*p<0.05).  
 
Figure 3. The effects of tetrabenazine to dose-dependently induce changes in behavioral 
performance on the concurrent lever pressing/chow feeding procedure in week three.  
Rats received IP injections of an acidified vehicle (VEH), 0.5mg/kg tetrabenazine (0.5 
TBZ), or 1.0mg/kg tetrabenazine (1.0 TBZ). (A) Mean (±SEM) number of lever presses 
(FR5 schedule during the 30 minutes session. (B) Mean (±SEM) gram quantity of chow 
intake. TBZ significantly suppressed lever pressing activity as compared to vehicle at 
1.0mg/kg (*p<0.05).  TBZ significantly increased chow consumption at a dose of 
1.0mg/kg (*p<0.05). 
 
Figure 4. The effects of reserpine to induce changes in behavioral performance on the 
concurrent lever pressing/chow feeding procedure, at 0.75mg/kg dose across weeks. (A) 
Mean (±SEM) number of lever presses (FR5 schedule during the 30 minutes session. (B) 
Mean (±SEM) gram quantity of chow intake. Reserpine significantly suppressed lever 
pressing activity at weeks two and three (*p<0.05).  Reserpine failed to produce 
significant increases in chow intake.  
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IX. FIGURES 
 
Figure 1. Week 1 dose-dependent behavioral effects of tetrabenazine 
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Figure 2. Week 2 dose-dependent behavioral effects of tetrabenazine. 
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Figure 3. Week 3 dose-dependent behavioral effects of tetrabenazine. 
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Figure 4. Dose-dependent behavioral effects of reserpine. 
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